Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Turbine","sponsor":"MSD Global Health Innovation","pharmaFlowCategory":"D","amount":"$20.7 million","upfrontCash":"Undisclosed","newsHeadline":"Turbine Raises \u20ac20 Million in Series A Financing to Advance Programs & Partnerships Towards the Clinic with World\u2019s First Cancer Cell Simulation Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"HUNGARY","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Turbine","sponsor":"Cancer Research Horizons","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Turbine\u2019s AI-powered Cancer Cell Simulations Will Be Used to Identify Novel Disease Positioning Strategies in Cancer Research UK\u2019s Latest Biotech Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"HUNGARY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Turbine","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Turbine Establishes Research Collaboration with Ono Pharmaceutical to Identify and Validate Novel Oncology Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"HUNGARY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Turbine","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Turbine Announces Collaboration to Uncover Biological Mechanisms of Drug Resistance in Hematological Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"HUNGARY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Turbine","sponsor":"Harmonic Discovery","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"HUNGARY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by Turbine

    Menu

    Turbine

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Turbine

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Hungary
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy

              Details:

              The collaboration aims to co-develop novel cancer therapies that will inhibit a dark kinase (NEK1) identified for cancer dependency using Turbine’s Simulated Cell™ platform.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Small molecule

              Partner/Sponsor/Collaborator: Harmonic Discovery

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 01, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Turbine

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Hungary
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Turbine Announces Collaboration to Uncover Biological Mechanisms of Drug Resistance in Hematological Cancers

              Details:

              Under the collaboration, Turbine will use its proprietary Simulated Cell™ platform to identify and understand mechanisms of resistance to therapy in hematological cancers.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Undisclosed

              Partner/Sponsor/Collaborator: AstraZeneca

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 05, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Turbine

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Hungary
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Turbine Establishes Research Collaboration with Ono Pharmaceutical to Identify and Validate Novel Oncology Targets

              Details:

              The collaboration aims to identify and validate novel targets within one of Ono’s priority domains of cancer biology. Turbine will apply its end-to-end, interpretable cell simulation technology, the Simulated Cell™ platform, to the in silico discovery of novel targets.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Ono Pharmaceutical

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration October 24, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Turbine

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Hungary
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Turbine’s AI-powered Cancer Cell Simulations Will Be Used to Identify Novel Disease Positioning Strategies in Cancer Research UK’s Latest Biotech Partnership

              Details:

              CRT’2199 originates from Cancer Research Horizons’ Therapeutic Innovation. CDC7 is a protein which plays a vital role in the regulation of cell division in normal cells.

              Lead Product(s): CRT’2199

              Therapeutic Area: Oncology Product Name: CRT’2199

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Cancer Research Horizons

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership January 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Turbine

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Hungary
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Turbine Raises €20 Million in Series A Financing to Advance Programs & Partnerships Towards the Clinic with World’s First Cancer Cell Simulation Platform

              Details:

              Turbine will use the financing proceeds to drive its next generation, potential first-in-class programs targeting DNA Damage Repair. These programs were the first ever to be selected using Turbine’s proprietary Simulated Cell.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Undisclosed

              Partner/Sponsor/Collaborator: MSD Global Health Innovation

              Deal Size: $20.7 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing November 22, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY